HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies
Year: 2012
Type: article
Study design: Observational Study
Abstract: The HLA class II DRB1 antigen DR15 is an important prognostic marker in immune-mediated marrow failure states. DR15 has also been associated with favorable outcomes (reduced acute graft-versus-host disease [aGVHD] and relapse) after allogeneic hematopoietic cell transplant. To elucidate the impact of DR15 on transplantation outcomes, we conducted a retrospective study of 2891 recipients of first allogeneic stem cell transplant from HLA-matched sibling donors for the treatment of acute leukemia, chronic myeloid leukemia, or myelodysplastic syndrome (MDS) between 1990 and 2007. All patients received conventional myeloablative conditioning, T-replete grafts, and cyclosporine plus methotrexate-based GVHD prophylaxis. DNA-based HLA typing allowed categorization of 732 patients (25.3%) as positive and 2159 patients (74.7%) as negative for DRB1*15:01 or *15:02 (DR15). There were no significant differences in baseline characteristics between the HLA DR15 positive and negative groups. In univariate analysis, HLA-DR15 status had no impact on neutrophil engraftment, aGVHD, chronic GVHD (cGVHD), treatment-related mortality, relapse, disease-free survival, or overall survival (OS). In multivariate analysis, DR15 status showed no significant difference in aGVHD, cGVHD, OS, or relapse. In conclusion, DR15 status had no impact on major HLA-matched sibling donor hematopoietic cell transplant outcomes in this large and homogenous cohort of patients with leukemia and MDS.
Authors: Minoo Battiwalla, Kristin Ellis, Peigang Li, Steven Z. Pavletic, Gorgun Akpek, Peiman Hematti, Thomas R. Klumpp, Richard T. Maziarz, Bipin N. Savani, Mahmoud D. Aljurf, Mitchell S. Cairo, William R. Drobyski, Biju George, Theresa Hahn, Nandita Khera, Mark R. Litzow, Alison W. Loren, Wael Saber, Mukta Arora, Alvaro Urbano-Ispizua, Corey Cutler, Mary E.D. Flowers, Stephen R. Spellman
Institutions: National Institutes of Health, National Heart, Lung, and Blood Institute, Medical College of Wisconsin, National Cancer Institute, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Oregon Health & Science University, Vanderbilt University, Vanderbilt University Medical Center, King Faisal Specialist Hospital & Research Centre, New York Medical College, Christian Medical College, Vellore, Roswell Park Comprehensive Cancer Center, Fred Hutch Cancer Center, Mayo Clinic, Abramson Cancer Center, University of Pennsylvania, University of Minnesota Medical Center, Hospital Clínic de Barcelona, Universitat de Barcelona, Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Funders: U.S. Department of Health and Human Services, Amgen, Teva Pharmaceutical Industries, Ariad Pharmaceuticals, Celgene, Blue Cross and Blue Shield Association, Medical College of Wisconsin, CellGenix, Kiadis Pharma, National Institutes of Health, Health Resources and Services Administration, Genentech, National Heart, Lung, and Blood Institute, Office of Naval Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases
Awards: G327847204, G3609734018, G3822637944, G3857372341, G4159847782, G4705346009, G4928541993, G5699415455, G6749775408, BMT Clinical Research Network Data Coordinating Center, G733025671, G8107732965, G833124618, G8876996369, G894505544, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, G909763084
OpenAlex ID: W2078021975